The representatives of the Taiwan pharmaceutical industry, led by Wang Yu-Pei (the Director of TRPMA), include delegates from over 20 pharmaceutical manufactures, covering new drugs, APIs, CROs and generics. The group visited four major pharmaceutical manufacturers in Korea (CMG, Kolon, Boryung and Alvogen) to find out more about the Korean’s drug R&D models and to contemplate applying their experiences to the strategies for helping Taiwanese manufacturers enter overseas markets.
Wang Yu-Pei expressed that the pharmaceutical industry in Korea has benefited from a series of reforms and become globalized. In the past decade, its export of pharmaceutical products increased by 3 folds. Korea is now the world’s 13th drug market. We can learn from the policies and regulations implemented in Korea, said Wang.
In Taiwan, Lotus Pharma has acquired a Korean drug manufacturer and the first drug license of PharmaEgine’s ONIVYDE in Asia is to be issued by the Korea authority. There are other talks about the authorization and collaboration on news drug clinical trials between Taiwan and Korea. In the meantime, the products involved in this collaboration agreement attract a lot of attention.
Wang Yu-Pei expressed that the collaboration agreement aims to improve the friendship and interests for both parties, to start collaborating on projects in which both parties are interested, to exchange the information and knowledge about medical technology and to find out more collaboration opportunities in the future.
(Translated by TRPMA)
More Information On China Times (Chinese Version)